The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor
The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the <i>CHEK2</i> recurrent...
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Journal article |
| Taal: | English |
| Gepubliceerd in: |
MDPI
2020
|
| _version_ | 1826298969241681920 |
|---|---|
| author | Brandão, A Paulo, P Maia, S Pinheiro, M Peixoto, A Cardoso, M Silva, MP Santos, C Eeles, RA Kote-Jarai, Z Muir, K Ukgpcs Collaborators Schleutker, J Wang, Y Pashayan, N Batra, J Apcb BioResource Grönberg, H Neal, DE Nordestgaard, BG Tangen, CM Southey, MC Wolk, A Albanes, D Haiman, CA Travis, RC Stanford, JL Mucci, LA West, CML Nielsen, SF Kibel, AS Cussenot, O Berndt, SI Koutros, S Sørensen, KD Cybulski, C Grindedal, EM Park, JY Ingles, SA Maier, C Hamilton, RJ Rosenstein, BS Vega, A The Impact Study Steering Committee And Collaborators Kogevinas, M Wiklund, F Penney, KL Brenner, H John, EM Kaneva, R |
| author_facet | Brandão, A Paulo, P Maia, S Pinheiro, M Peixoto, A Cardoso, M Silva, MP Santos, C Eeles, RA Kote-Jarai, Z Muir, K Ukgpcs Collaborators Schleutker, J Wang, Y Pashayan, N Batra, J Apcb BioResource Grönberg, H Neal, DE Nordestgaard, BG Tangen, CM Southey, MC Wolk, A Albanes, D Haiman, CA Travis, RC Stanford, JL Mucci, LA West, CML Nielsen, SF Kibel, AS Cussenot, O Berndt, SI Koutros, S Sørensen, KD Cybulski, C Grindedal, EM Park, JY Ingles, SA Maier, C Hamilton, RJ Rosenstein, BS Vega, A The Impact Study Steering Committee And Collaborators Kogevinas, M Wiklund, F Penney, KL Brenner, H John, EM Kaneva, R |
| author_sort | Brandão, A |
| collection | OXFORD |
| description | The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the <i>CHEK2</i> recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case-control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The <i>CHEK2</i> missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1-3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with <i>CHEK2</i> c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families. |
| first_indexed | 2024-03-07T04:54:49Z |
| format | Journal article |
| id | oxford-uuid:d6390574-70bd-43c1-a8f5-b17d03e172d8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:54:49Z |
| publishDate | 2020 |
| publisher | MDPI |
| record_format | dspace |
| spelling | oxford-uuid:d6390574-70bd-43c1-a8f5-b17d03e172d82022-03-27T08:32:04ZThe CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestorJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d6390574-70bd-43c1-a8f5-b17d03e172d8EnglishSymplectic ElementsMDPI2020Brandão, APaulo, PMaia, SPinheiro, MPeixoto, ACardoso, MSilva, MPSantos, CEeles, RAKote-Jarai, ZMuir, KUkgpcs CollaboratorsSchleutker, JWang, YPashayan, NBatra, JApcb BioResourceGrönberg, HNeal, DENordestgaard, BGTangen, CMSouthey, MCWolk, AAlbanes, DHaiman, CATravis, RCStanford, JLMucci, LAWest, CMLNielsen, SFKibel, ASCussenot, OBerndt, SIKoutros, SSørensen, KDCybulski, CGrindedal, EMPark, JYIngles, SAMaier, CHamilton, RJRosenstein, BSVega, AThe Impact Study Steering Committee And CollaboratorsKogevinas, MWiklund, FPenney, KLBrenner, HJohn, EMKaneva, RThe identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the <i>CHEK2</i> recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case-control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The <i>CHEK2</i> missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1-3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with <i>CHEK2</i> c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families. |
| spellingShingle | Brandão, A Paulo, P Maia, S Pinheiro, M Peixoto, A Cardoso, M Silva, MP Santos, C Eeles, RA Kote-Jarai, Z Muir, K Ukgpcs Collaborators Schleutker, J Wang, Y Pashayan, N Batra, J Apcb BioResource Grönberg, H Neal, DE Nordestgaard, BG Tangen, CM Southey, MC Wolk, A Albanes, D Haiman, CA Travis, RC Stanford, JL Mucci, LA West, CML Nielsen, SF Kibel, AS Cussenot, O Berndt, SI Koutros, S Sørensen, KD Cybulski, C Grindedal, EM Park, JY Ingles, SA Maier, C Hamilton, RJ Rosenstein, BS Vega, A The Impact Study Steering Committee And Collaborators Kogevinas, M Wiklund, F Penney, KL Brenner, H John, EM Kaneva, R The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor |
| title | The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor |
| title_full | The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor |
| title_fullStr | The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor |
| title_full_unstemmed | The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor |
| title_short | The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor |
| title_sort | the chek2 variant c 349a g is associated with prostate cancer risk and carriers share a common ancestor |
| work_keys_str_mv | AT brandaoa thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT paulop thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT maias thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT pinheirom thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT peixotoa thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT cardosom thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT silvamp thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT santosc thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT eelesra thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT kotejaraiz thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT muirk thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT ukgpcscollaborators thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT schleutkerj thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT wangy thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT pashayann thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT batraj thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT apcbbioresource thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT gronbergh thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT nealde thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT nordestgaardbg thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT tangencm thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT southeymc thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT wolka thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT albanesd thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT haimanca thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT travisrc thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT stanfordjl thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT muccila thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT westcml thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT nielsensf thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT kibelas thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT cussenoto thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT berndtsi thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT koutross thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT sørensenkd thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT cybulskic thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT grindedalem thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT parkjy thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT inglessa thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT maierc thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT hamiltonrj thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT rosensteinbs thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT vegaa thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT theimpactstudysteeringcommitteeandcollaborators thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT kogevinasm thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT wiklundf thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT penneykl thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT brennerh thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT johnem thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor AT kanevar thechek2variantc349agisassociatedwithprostatecancerriskandcarriersshareacommonancestor |